At a glance
- Originator Merck & Co
- Class Antiplatelets; Vascular disorder therapies
- Mechanism of Action GPIIb-IIIa antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Thrombosis
Most Recent Events
- 17 Feb 2000 New profile
- 17 Feb 2000 Preclinical development for Thrombosis in USA (PO)